Amneal Pharmaceuticals
AMRX
128 hedge funds and large institutions have $302M invested in Amneal Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 27 closing their positions.
181% more call options, than puts
Call options by funds: $331K | Put options by funds: $118K
124% more capital invested
Capital invested by funds: $135M → $302M (+$167M)
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.33% less ownership
Funds ownership: 63.88% → 63.56% (-0.33%)
11% less funds holding
Funds holding: 144 → 128 (-16)
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.54M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.51M |
| 3 |
BlackRock
New York
|
+$1.66M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.49M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$856K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.4M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.16M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$2.73M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.82M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$306K |
AMRX Hedge Fund Activity: Q2 2023 in Review
128 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2023, worth a combined $302M — up 124% from $135M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of AMRX and 11 opened new positions — a net loss of 16 holders — while 39 trimmed existing stakes and 48 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $5.54M. The largest seller was Millennium Management, cutting an estimated $4.4M.
- 128 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2023, down from 144 in Q1 2023.
- Funds reported $302M of Amneal Pharmaceuticals stock for Q2 2023, up 124% quarter-over-quarter.
- 11 funds opened new Amneal Pharmaceuticals positions in Q2 2023 and 27 closed out, a net change of -16 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2023 was Rubric Capital Management (New York), an estimated $5.54M added.
- The largest Amneal Pharmaceuticals seller in Q2 2023 was Millennium Management, an estimated $4.4M sold.
Based on aggregated 13F filings for Q2 2023.